EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocul...
Q2 2026
Aug 5, 2026
Q1 2026
May 7, 2026
FY 2025
Mar 5, 2026
Q4 2025
Q3 2025
Nov 6, 2025
